ACADIA Pharmaceuticals (LTS:0A4W) FFO


LTS:0A4W ACADIA Pharmaceuticals Inc LTS:0A4W
76 GF Score
Price $26.87
GF Value $26.80
! 9 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0A4W
76GF Score
ACADIA Pharmaceuticals Inc LTS:0A4W
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ACADIA Pharmaceuticals (LTS:0A4W) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of $26.87 is trading 0.3% above its estimated GF Value™ of $26.80.

Key valuation signals for LTS:0A4W:

  • FFO:
  • GF Value™: $26.80 vs. price of $26.87 (0.3% above fair value)
  • GF Score™: 76/100 with 9 warning signs

No single metric tells the full story. See the LTS:0A4W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for LTS:0A4W

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.87
Price
$26.80
GF Value